Navigation Links
Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
Date:9/3/2008

of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of the SB-509 clinical trials, whether the SB-509 clinical trials will validate and support safety, tolerability and efficacy of SB-509, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See Sangamo's SEC filings, and in particular, the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... N.J. , Sept. 17, 2014  Bayer HealthCare ... National Hemophilia Foundation,s 66 th Annual Meeting, which ... , D.C.  The data, which will be shared through ... treatment and patient care. Data will be presented in ... research into treatment modalities in hemophilia A patients, Bayer ...
(Date:9/17/2014)... EMERYVILLE, Calif. , Sept. 17, 2014 /PRNewswire/ ... newest data analytics solution that brings complete visibility ... minimize risks in an ever-evolving reimbursement landscape. Powered ... Integrity brings transparency to the critical point between ... operations impact revenue. The solution will improve revenue ...
(Date:9/17/2014)... 2014 Women everywhere know how frustrating a ... uncomfortable, they,re often also embarrassing and have a way ... Support ( http://ph-defense.com ) is a new, over-the-counter product ... homeopathic product. Odor, discharge, and discomfort ... infection. In many cases, the cause of such problems ...
Breaking Medicine Technology:Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3New Product from Vireo Systems: pH-D Feminine Health Support 2
... 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... to reprise key carfilzomib data presentations that were featured at ... San Diego, California. The teleconference will begin at ... Interested parties may access the teleconference and the presentation that ...
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... diagnostic ("IVD") company, responded today to the allegations raised ... dated December 6, 2011. The Company maintains that the ... "Report") concern matters which have long been disclosed in ...
Cached Medicine Technology:China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 2China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 3China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 4China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 5China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 6
(Date:9/18/2014)... (PRWEB) September 18, 2014 According to the ... from eczema, with many of them being children. In fact, ... diagnosed as babies and children. The millions of children who ... be brought on by eczema. A new book has been ... they are and to find relief from the condition over ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 SpineFrontier ... team and surgeon partners in Less Exposure Surgery ... SpineFrontier, Tamara authored an extensive education curriculum and ... Masters in Science in Organizational Leadership, and has ... for eleven years. Bringing her to the team ...
(Date:9/18/2014)... 18, 2014 First Choice Emergency ... rooms in the United States, named Douglas J. Harrison, ... City-Lakes facility. , “We are pleased to welcome ... director of our new Missouri City-Lakes facility,” said Dr. ... Emergency Room. , Dr. Harrison received his undergraduate ...
(Date:9/18/2014)... N-Zyme Scientifics LLC achieved a major developmental milestone ... mere 8 months after company startup. Its novel product ... enzyme used in the “Biologics” industry for discovery and ... pathology on Mass Spec devices. PRIME™ is being sold ... market (PNGase F PRIMETM). N-Zyme is currently evaluating ...
(Date:9/17/2014)... September 18, 2014 Recently, BambooIndustry.com, an outstanding ... of bamboo floorings . There are more than 1000 ... has launched a big promotion for these useful items. Each ... 30 % off. , “We are very proud to ... to say, all these items are made with natural materials ...
Breaking Medicine News(10 mins):Health News:New Book Helps Millions of Children Deal With The Emotional Pains of Suffering From Eczema 2Health News:SpineFrontier Inc. Makes Bold Move to Expand Its Internal Training Team to Collaborate With The LESSociety’s Less Exposure Surgery® University To Educate Surgeons. 2Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:More Than 1000 Items Added To BambooIndustry.com’s Bamboo Flooring Collection 2
... a newly developed drug, which is aimed at a particular ... tumour growth, is active in patients with advanced cancers and, ... The drug, ACE-041, targets a different molecular pathway to ... treat cancer. Results from a phase I clinical ...
... surgery should receive a risk assessment before their procedure ... in the legs or lungs, according to research at ... that 1 in 9 patients at highest risk based ... clot-preventing medications after surgery. Published in the November ...
... into mice with metastatic melanoma has resulted in permanent ... cancer, according to an article to be published in ... Clinical Investigation . The online version is now available. ... modified lentivirus to introduce a potent anti-melanoma T cell ...
... federal agencies recently cosponsored a set of expert work ... to psychological adjustment and traumatic brain injury (TBI). ... behavioral neuroscience at Boston University School of Medicine, chaired ... Dr. Kaloupek,s work at the National Center for PTSD ...
... of six national participants in a pilot study that ... families have a smoother care experience and better outcomes ... to reliably adhere to best practice standards. The ... the Society of Thoracic Surgeons (STS) will study clinician ...
... have been stymied for years over the fact that people ... response to the pathogen antibodies that turn out to ... Medical Center can explain why: Some of the earliest and ... the virus until after it,s already invaded a healthy cell. ...
Cached Medicine News:Health News:Researchers find new target for stopping tumors developing their own blood supply 2Health News:Researchers find new target for stopping tumors developing their own blood supply 3Health News:Assessment tool predicts blood clot risk after plastic surgery 2Health News:Assessment tool predicts blood clot risk after plastic surgery 3Health News:Gene therapy for metastatic melanoma in mice produces complete remission 2Health News:Researchers identify PTSD measures for use in traumatic brain injury research 2Health News:Lung cancer patients are the centerpiece for Northwestern medicine quality of care study 2Health News:Why so many antibodies fail to protect against HIV infection 2
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: